- ASSOCIATE PROFESSOR | Pathology
- ASSOCIATE PROFESSOR | Psychiatry
- Clinical Pathology
- Anatomic Pathology
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Autopsy neuropathology
- Surgical neuropathology
MD, B. J. Medical College
Newcastle General Hospital
Northern General Hospital
The Royal College of Pathologists
Newcastle General Hospital
Neurobiology of Neurodegenerative Diseases
The Neuropathology Laboratory and Brain Bank for Neurodegenerative Disorders provide neuropathology support to several federally funded grants for research projects on Alzheimer's disease, Parkinson disease and allied neurodegenerative diseases, and schizophrenia. The laboratory also offers specialized diagnostic reference facility for neurodegenerative disorders. The fully equipped laboratory conducts detailed descriptive studies to document the extent and distribution of various neuropathologic lesions in human brains obtained at autopsy from patients affected by a wide range of neurodegenerative diseases. The resulting characterization of morphologic lesions, diagnosis and clinicopathological correlation of the longitudinally studied cases become an integral part of several grant funded research studies. Our laboratory also has an extensive repository of study material of parkinsonism dementia complex (PDC) of Guam and the recently observed overlap of Alzheimer's disease in the Chamorro, the native inhabitants of Guam and other Marianas islands. Our study also involves the extent of overlap between morphologic changes encountered in other more common neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and allied movement disorders, Lewy body dementia, vascular dementia and variants of frontal lobe degeneration. Recently, we have focused our research activity on age-related cognitive disorders in the population of developing countries (or low and middle-income countries, as defined by the World Bank Survey of world economies) under a federally funded clinical and pathologic study on dementia and ageing in India and carry out necessary research capacity building there.
Purohit DP, Dick DJ, Perry RH, Lyons PR, Schofield IS, Foster JB. Solitary extranodal lymphoma of sciatic nerve.. J Neurol Sci. 1986; 74: 23-34.
Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, Candy JM, Edwardson JA, Fairbairn A. Cholinergic receptors in cognitive disorders.. Can J Neurol Sci. 1986; 13 (supplement): 521-527.
Purohit DP, Perl DP. Proposal to revise the morphologic criteria for the diagnosis of Alzheimer's disease.. Neurobiol Aging 1997; 18: S81-S94.
Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Losonczy M, Davis KL. Alzheimer's disease and related neurodegenerative diseases in elderly schizophrenic patients: a post-mortem neuropathologic study of 100 cases.. Arch Gen Psychiatry 1998;: 205-211.
Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Regional distribution of senile plaques in non-demented elderly and subjects with very mild Alzheimer's disease.. Arch Neurol. 1998; 55: 1185-1191.
Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers are not decreased in early Alzheimer's disease. . JAMA 1999; 281: 1401-1406.
Yahr MD, Orosz D, Purohit DP. Co-occurrence of essential tremor and Parkinsos disease: Clinical study of a large kindred with autopsy findings. Parkinsonism and Related Disorders 2003; 9: 225-231.
Perl DP, Hof PR, Purohit DP, Loerzel AJ, Kakulas BA. Hippocampal and entorhinal cortex neurofibrillary tangle formation in Guamanian Chamorros free of overt neurologic dysfunction. . J Neuropathol Exp Neurol. 2003; 62: 381-388.
Benveniste RJ, Purohit DP, Byun H. Pituicytoma presenting with spontaneous hemorrhage: Case report.. Pituitary 2006; 9: 53-58.
Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression.. Am J Geriatr Psychiatry. 2008 Feb; 16(2): 168-174.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Purohit did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.